Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: Modulation of VEGF and VEGF-related proteins Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Carcinoma, Renal Cell
  • Indoles
  • Kidney Neoplasms
  • Neoplasm Proteins
  • Pyrroles
  • Vascular Endothelial Growth Factors

abstract

  • Sunitinib treatment in advanced RCC patients leads to modulation of plasma levels of circulating proteins involved in VEGF signaling, including soluble forms of two VEGF receptors. This panel of proteins may be of value as biomarkers of the pharmacological and clinical activity of sunitinib in RCC, and of angiogenic processes in cancer and other diseases.

publication date

  • July 2, 2007

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC1939830

Digital Object Identifier (DOI)

  • 10.1186/1479-5876-5-32

PubMed ID

  • 17605814

Additional Document Info

start page

  • 32

volume

  • 5